Reply to: Statistical and Methodological Considerations in the Evaluation of Ultra-Low-Dose Nivolumab
Journal of Clinical Oncology · 10.11.2026 · 44 (32) · 3175-3176
DOI: 10.1200/jco-26-01376 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.11.2026. Verfasst von Kumar Prabhash und 4 weiteren Autor:innen. Beteiligte Einrichtung: Kumar Prabhash, MD, DM, MBBS, Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India, Department of Me…. Die Arbeit nennt 4 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Kumar Prabhash, MD, DM, MBBS, Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India, Department of Medical Oncology, Homi Bhabha Cancer Hospital and Research Centre, Muzaf…
ORCID-Profile: Kumar Prabhash, Vanita Noronha, Akash Pawar, Rajendra Badwe
Zitieren
APA
Prabhash, K., Noronha, V., Pawar, A., Shetake, A., & Badwe, R. (2026). Reply to: Statistical and Methodological Considerations in the Evaluation of Ultra-Low-Dose Nivolumab. Journal of Clinical Oncology, 44(32), 3175-3176. https://doi.org/10.1200/jco-26-01376
Vancouver
Prabhash K, Noronha V, Pawar A, Shetake A, Badwe R. Reply to: Statistical and Methodological Considerations in the Evaluation of Ultra-Low-Dose Nivolumab. Journal of Clinical Oncology. 2026;44(32):3175-3176. doi:10.1200/jco-26-01376
BibTeX
@article{Prabhash2026,
author = {Prabhash, Kumar and Noronha, Vanita and Pawar, Akash and Shetake, Ankush and Badwe, Rajendra},
title = {Reply to: Statistical and Methodological Considerations in the Evaluation of Ultra-Low-Dose Nivolumab},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {32},
pages = {3175--3176},
doi = {10.1200/jco-26-01376}
}
EUVIMED